Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 417

1.

Curcumin-galactomannoside complex inhibits pathogenesis in Ox-LDL-challenged human peripheral blood mononuclear cells.

Saji S, Asha S, Svenia PJ, Ratheesh M, Sheethal S, Sandya S, Krishnakumar IM.

Inflammopharmacology. 2018 Apr 9. doi: 10.1007/s10787-018-0474-0. [Epub ahead of print]

PMID:
29633105
2.

Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models.

Satake T, Suetsugu A, Nakamura M, Hasegawa K, Kunisada T, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2018 Apr;38(4):1927-1935.

PMID:
29599308
3.

Visualizing the Tumor Microenvironment by Color-coded Imaging in Orthotopic Mouse Models of Cancer.

Suetsugu A, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2018 Apr;38(4):1847-1857. Review.

PMID:
29599301
4.

The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study.

Takuwa H, Saji S, Takada M, Takahara S, Yamauchi A.

Breast Dis. 2018 Mar 19. doi: 10.3233/BD-170307. [Epub ahead of print]

PMID:
29578459
5.

Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.

Mayanagi S, Kashiwabara K, Honda M, Oba K, Aoyama T, Kanda M, Maeda H, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T.

Dis Colon Rectum. 2018 Mar 20. doi: 10.1097/DCR.0000000000001002. [Epub ahead of print]

PMID:
29561282
6.

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial.

Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M.

ESMO Open. 2018 Feb 14;3(2):e000314. doi: 10.1136/esmoopen-2017-000314. eCollection 2018.

7.

Clinical Signatures of Mucinous and Poorly Differentiated Subtypes of Colorectal Adenocarcinomas by a Propensity Score Analysis of an Independent Patient Database from Three Phase III Trials.

Kanda M, Oba K, Aoyama T, Kashiwabara K, Mayanagi S, Maeda H, Honda M, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T; Japanese Foundation for Multidisciplinary Treatment of Cancer.

Dis Colon Rectum. 2018 Apr;61(4):461-471. doi: 10.1097/DCR.0000000000001022.

PMID:
29521828
8.

A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib.

Kimura-Tsuchiya R, Sasaki E, Nakamura I, Suzuki S, Kawana S, Okouchi C, Fukushima T, Hashimoto Y, Suzuki S, Saji S.

Case Rep Oncol. 2018 Feb 9;11(1):75-80. doi: 10.1159/000486569. eCollection 2018 Jan-Apr.

9.

Impact of physiological hormonal fluctuations on 18F-fluorodeoxyglucose uptake in breast cancer.

Miyake KK, Nakamoto Y, Saji S, Sugie T, Kurihara K, Kanao S, Ikeda DM, Toi M, Togashi K.

Breast Cancer Res Treat. 2018 Feb 8. doi: 10.1007/s10549-018-4711-4. [Epub ahead of print]

PMID:
29423901
10.

Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.

Ogiya R, Niikura N, Kumaki N, Yasojima H, Iwasa T, Kanbayashi C, Oshitanai R, Tsuneizumi M, Watanabe KI, Matsui A, Fujisawa T, Saji S, Masuda N, Tokuda Y, Iwata H.

Oncotarget. 2017 Oct 27;8(61):103671-103681. doi: 10.18632/oncotarget.22110. eCollection 2017 Nov 28.

11.

Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials.

Honda M, Oba K, Akiyoshi T, Maeda H, Kashiwabara K, Kanda M, Mayanagi S, Aoyama T, Hamada C, Sadahiro S, Fukunaga Y, Ueno M, Sakamoto J, Saji S, Yoshikawa T.

Oncotarget. 2017 Oct 12;8(58):99150-99160. doi: 10.18632/oncotarget.21845. eCollection 2017 Nov 17.

12.

Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials.

Maeda H, Kashiwabara K, Aoyama T, Oba K, Honda M, Mayanagi S, Kanda M, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T.

J Cancer. 2017 Oct 23;8(19):4057-4064. doi: 10.7150/jca.21365. eCollection 2017.

13.

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).

Ishiguro H, Saji S, Nomura S, Tanaka S, Ueno T, Onoue M, Iwata H, Yamanaka T, Sasaki Y, Toi M.

Cancer Med. 2017 Dec;6(12):2909-2917. doi: 10.1002/cam4.1258. Epub 2017 Nov 13.

14.

Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.

Curr Med Res Opin. 2018 Jan;34(1):49-54. doi: 10.1080/03007995.2017.1400426. Epub 2017 Nov 21.

PMID:
29095648
15.

Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial).

Okuno K, Aoyama T, Oba K, Yokoyama N, Matsuhashi N, Kunieda K, Nishimura Y, Akamatsu H, Kobatake T, Morita S, Yoshikawa T, Sakamoto J, Saji S.

Cancer Chemother Pharmacol. 2018 Jan;81(1):65-71. doi: 10.1007/s00280-017-3466-7. Epub 2017 Nov 1.

16.

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.

Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T, Chin K, Boku N, Omuro Y, Komatsu Y, Hamamoto Y, Koizumi W, Saji S, Shah MA, Van Cutsem E, Kang YK, Iwasaki J, Kuriki H, Ohtsuka W, Ohtsu A.

Gastric Cancer. 2018 May;21(3):429-438. doi: 10.1007/s10120-017-0773-y. Epub 2017 Oct 20.

17.

Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials.

Aoyama T, Kashiwabara K, Oba K, Honda M, Sadahiro S, Hamada C, Maeda H, Mayanagi S, Kanda M, Sakamoto J, Saji S, Yoshikawa T.

Cancer Med. 2017 Nov;6(11):2523-2530. doi: 10.1002/cam4.1208. Epub 2017 Sep 25.

18.

Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.

Niikura N, Shimomura A, Fukatsu Y, Sawaki M, Ogiya R, Yasojima H, Fujisawa T, Yamamoto M, Tsuneizumi M, Kitani A, Watanabe J, Matsui A, Takahashi Y, Takashima S, Shien T, Tamura K, Saji S, Masuda N, Tokuda Y, Iwata H.

Breast Cancer Res Treat. 2018 Jan;167(1):81-87. doi: 10.1007/s10549-017-4489-9. Epub 2017 Sep 11.

PMID:
28895005
19.

[III. Novel Endocrine Therapy with Signal Transduction Inhibitors for Hormone Dependent Breast Cancer].

Tachibana K, Ohtake T, Saji S.

Gan To Kagaku Ryoho. 2016 Dec;43(13):2509-2512. Japanese. No abstract available.

PMID:
28676614
20.

Imaging the Role of Multinucleate Pancreatic Cancer Cells and Cancer-Associated Fibroblasts in Peritoneal Metastasis in Mouse Models.

Hasegawa K, Suetsugu A, Nakamura M, Matsumoto T, Aoki H, Kunisada T, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2017 Jul;37(7):3435-3440.

PMID:
28668832
21.

Choline-Deficient-Diet-Induced Fatty Liver Is a Metastasis-Resistant Microenvironment.

Nakamura M, Suetsugu A, Hasegawa K, Matsumoto T, Aoki H, Kunisada T, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2017 Jul;37(7):3429-3434.

PMID:
28668831
22.

Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).

Tanaka H, Kanda M, Morita S, Taguri M, Nishikawa K, Shimada M, Muguruma K, Koeda K, Takahashi M, Nakamori M, Konno H, Tsuji A, Hosoya Y, Shirasaka T, Yamamitsu S, Sowa M, Kitajima M, Okajima M, Kobayashi M, Sakamoto J, Saji S, Hirakawa K.

Int J Clin Oncol. 2017 Dec;22(6):1052-1059. doi: 10.1007/s10147-017-1157-3. Epub 2017 Jun 30.

23.

Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients' data from three large phase III randomized trials.

Aoyama T, Oba K, Honda M, Sadahiro S, Hamada C, Mayanagi S, Kanda M, Maeda H, Kashiwabara K, Sakamoto J, Saji S, Yoshikawa T.

Cancer Med. 2017 Jul;6(7):1573-1580. doi: 10.1002/cam4.1126. Epub 2017 Jun 22.

24.

Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study.

Ozaki A, Nomura S, Leppold C, Tsubokura M, Tanimoto T, Yokota T, Saji S, Sawano T, Tsukada M, Morita T, Ochi S, Kato S, Kami M, Nemoto T, Kanazawa Y, Ohira H.

BMC Cancer. 2017 Jun 19;17(1):423. doi: 10.1186/s12885-017-3412-4.

25.

Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.

Suto T, Ishiguro M, Hamada C, Kunieda K, Masuko H, Kondo K, Ishida H, Nishimura G, Sasaki K, Morita T, Hazama S, Maeda K, Mishima H, Ike H, Sadahiro S, Sugihara K, Okajima M, Saji S, Sakamoto J, Tomita N.

Int J Clin Oncol. 2017 Aug;22(4):805-806. doi: 10.1007/s10147-017-1146-6. No abstract available.

PMID:
28608229
26.

Free Active Chlorine in Sodium Hypochlorite Solutions Admixed with Octenidine, SmearOFF, Chlorhexidine, and EDTA.

Krishnan U, Saji S, Clarkson R, Lalloo R, Moule AJ.

J Endod. 2017 Aug;43(8):1354-1359. doi: 10.1016/j.joen.2017.03.034. Epub 2017 May 31.

PMID:
28577962
27.

Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29-0003.

Kusano M, Honda M, Okabayashi K, Akimaru K, Kino S, Tsuji Y, Watanabe M, Suzuki S, Yoshikawa T, Sakamoto J, Oba K, Saji S.

J Cancer Res Ther. 2017 Jan-Mar;13(1):84-90. doi: 10.4103/0973-1482.184524.

28.

Genetic Recombination Between Stromal and Cancer Cells Results in Highly Malignant Cells Identified by Color-Coded Imaging in a Mouse Lymphoma Model.

Nakamura M, Suetsugu A, Hasegawa K, Matsumoto T, Aoki H, Kunisada T, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

J Cell Biochem. 2017 Dec;118(12):4216-4221. doi: 10.1002/jcb.26068. Epub 2017 Jun 9.

PMID:
28419513
29.

Estrogen-Related Factors in the Frontal Lobe of Alzheimer's Disease Patients and Importance of Body Mass Index.

Honma N, Saji S, Mikami T, Yoshimura N, Mori S, Saito Y, Murayama S, Harada N.

Sci Rep. 2017 Apr 7;7(1):726. doi: 10.1038/s41598-017-00815-3.

30.

Ozone-Sensitive Arabidopsis Mutants with Deficiencies in Photorespiratory Enzymes.

Saji S, Bathula S, Kubo A, Tamaoki M, Aono M, Sano T, Tobe K, Timm S, Bauwe H, Nakajima N, Saji H.

Plant Cell Physiol. 2017 May 1;58(5):914-924. doi: 10.1093/pcp/pcx027.

PMID:
28339978
31.

Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yamamoto Y, Ohno S, Toi M.

Breast Cancer Res Treat. 2017 Jun;163(3):545-554. doi: 10.1007/s10549-017-4212-x. Epub 2017 Mar 23.

PMID:
28337663
32.

Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.

Suto T, Ishiguro M, Hamada C, Kunieda K, Masuko H, Kondo K, Ishida H, Nishimura G, Sasaki K, Morita T, Hazama S, Maeda K, Mishima H, Ike H, Sadahiro S, Sugihara K, Okajima M, Saji S, Sakamoto J, Tomita N.

Int J Clin Oncol. 2017 Jun;22(3):494-504. doi: 10.1007/s10147-016-1083-9. Epub 2017 Jan 11. Erratum in: Int J Clin Oncol. 2017 Aug;22(4):805-806.

33.

Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.

Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M.

Breast Cancer Res. 2016 Dec 19;18(1):129.

34.

Atomic scattering factor of the ASTRO-H (Hitomi) SXT reflector around the gold's L edges.

Kikuchi N, Kurashima S, Ishida M, Iizuka R, Maeda Y, Hayashi T, Okajima T, Matsumoto H, Mitsuishi I, Saji S, Sato T, Tachibana S, Mori H, Christensen F, Brejnholt N, Nitta K, Uruga T.

Opt Express. 2016 Oct 31;24(22):25548-25564. doi: 10.1364/OE.24.025548.

PMID:
27828493
35.

Color-coded Imaging Enables Fluorescence-guided Surgery to Resect the Tumor Along with the Tumor Microenvironment in a Syngeneic Mouse Model of EL-4 Lymphoma.

Hasegawa K, Suetsugu A, Nakamura M, Matsumoto T, Kunisada T, Shimizu M, Saji S, Moriwaki H, Bouvet M, Hoffman RM.

Anticancer Res. 2016 Sep;36(9):4443-8.

PMID:
27630280
36.

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102).

Nishikawa K, Takahashi T, Takaishi H, Miki A, Noshiro H, Yoshikawa T, Nishida Y, Iwasa S, Miwa H, Masuishi T, Boku N, Yamada Y, Kodera Y, Yoshida K, Morita S, Sakamoto J, Saji S, Kitagawa Y.

Int J Cancer. 2017 Jan 1;140(1):188-196. doi: 10.1002/ijc.30383. Epub 2016 Oct 6.

37.

Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701).

Yoshino S, Nishikawa K, Morita S, Takahashi T, Sakata K, Nagao J, Nemoto H, Murakami N, Matsuda T, Hasegawa H, Shimizu R, Yoshikawa T, Osanai H, Imano M, Naitoh H, Tanaka A, Tajiri T, Gochi A, Suzuki M, Sakamoto J, Saji S, Oka M.

Eur J Cancer. 2016 Sep;65:164-71. doi: 10.1016/j.ejca.2016.06.012. Epub 2016 Aug 5.

38.

Color-coded Live Imaging of Heterokaryon Formation and Nuclear Fusion of Hybridizing Cancer Cells.

Suetsugu A, Matsumoto T, Hasegawa K, Nakamura M, Kunisada T, Shimizu M, Saji S, Moriwaki H, Bouvet M, Hoffman RM.

Anticancer Res. 2016 Aug;36(8):3827-31.

PMID:
27466484
39.

Social isolation and cancer management after the 2011 triple disaster in Fukushima, Japan: A case report of breast cancer with patient and provider delay.

Ozaki A, Leppold C, Tsubokura M, Tanimoto T, Saji S, Kato S, Kami M, Tsukada M, Ohira H.

Medicine (Baltimore). 2016 Jun;95(26):e4027. doi: 10.1097/MD.0000000000004027.

40.

Dental abrasion as a cutting process.

Lucas PW, Wagner M, Al-Fadhalah K, Almusallam AS, Michael S, Thai LA, Strait DS, Swain MV, van Casteren A, Renno WM, Shekeban A, Philip SM, Saji S, Atkins AG.

Interface Focus. 2016 Jun 6;6(3):20160008. doi: 10.1098/rsfs.2016.0008.

41.

[Combination Therapy of Molecular-Targeted Drugs for Breast Cancer -- Their Potential in the Future].

Okano M, Ohtake T, Saji S.

Gan To Kagaku Ryoho. 2016 Apr;43(4):398-403. Japanese.

PMID:
27220784
42.

Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).

Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Ishigure K, Hasegawa J, Munemoto Y, Matsui T, Takagane A, Ishikawa H, Matsumoto S, Sakamoto J, Saji S, Yoshino T, Ohtsu A, Watanabe T, Matsuda F.

Ann Oncol. 2016 Jun;27(6):1143-8. doi: 10.1093/annonc/mdw074. Epub 2016 Feb 18.

PMID:
27069012
43.

A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).

Oki E, Murata A, Yoshida K, Maeda K, Ikejiri K, Munemoto Y, Sasaki K, Matsuda C, Kotake M, Suenaga T, Matsuda H, Emi Y, Kakeji Y, Baba H, Hamada C, Saji S, Maehara Y.

Ann Oncol. 2016 Jul;27(7):1266-72. doi: 10.1093/annonc/mdw162. Epub 2016 Apr 7.

44.

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.

Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M.

BMC Cancer. 2016 Mar 16;16:230. doi: 10.1186/s12885-016-2270-9.

45.

Active sites of nitrogen-doped carbon materials for oxygen reduction reaction clarified using model catalysts.

Guo D, Shibuya R, Akiba C, Saji S, Kondo T, Nakamura J.

Science. 2016 Jan 22;351(6271):361-5. doi: 10.1126/science.aad0832.

46.

Structure and scale of the mechanics of mammalian dental enamel viewed from an evolutionary perspective.

Lucas PW, Philip SM, Al-Qeoud D, Al-Draihim N, Saji S, van Casteren A.

Evol Dev. 2016 Jan-Feb;18(1):54-61. doi: 10.1111/ede.12169. Epub 2015 Dec 14.

PMID:
26763592
47.

[Save the post-market cancer clinical trials in Japan--their benefit to society must not be forgotten].

Saji S.

Gan To Kagaku Ryoho. 2015 Oct;42(10):1179-82. Japanese. No abstract available.

PMID:
26665418
48.

Erratum to: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).

Matsusaka S, Nashimoto A, Nishikawa K, Miki A, Miwa H, Yamaguchi K, Yoshikawa T, Ochiai A, Morita S, Sano T, Kodera Y, Kakeji Y, Sakamoto J, Saji S, Yoshida K.

Gastric Cancer. 2016 Jul;19(3):1026. No abstract available.

49.

Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?

Saji S, Kimura-Tsuchiya R, Sasaki E.

Breast Cancer. 2016 Jan;23(1):1-3. doi: 10.1007/s12282-015-0657-0. No abstract available.

PMID:
26534859
50.

Recruitment of Cancer-Associated Fibroblasts and Blood Vessels by Orthotopic Liver Tumors Imaged in Red Fluorescent Protein (RFP) Transgenic Nude Mice.

Suetsugu A, Hiroshima Y, Matsumoto T, Hasagawa K, Nakamura M, Shimizu M, Saji S, Moriwaki H, Bouvet M, Hoffman RM.

Anticancer Res. 2015 Nov;35(11):5821-5.

PMID:
26504003

Supplemental Content

Support Center